Study immune changes after AML relapse after bone marrow transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how the immune system changes when acute myeloid leukemia (AML) comes back after a donor stem cell transplant. It may help researchers create more personalized treatment plans and future guidelines for how to care for people in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with acute myeloid leukemia (AML) that has come back after an allogeneic stem cell transplant from a donor
- Your transplant came from a donor either related or unrelated, and it may have been bone marrow, peripheral blood stem cells, or cord blood
- You must be willing to sign the study consent form
- You must have stored blood/biologic samples available through a specific leukemia biobank (so researchers can study what’s happening in your body)
- You cannot join another clinical protocol if that protocol would block participation in other studies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
This study uses blood samples from people with acute myeloid leukemia (AML) and from healthy stem cell donors to learn how to make immune cells better at killing cancer. The goal is to develop a new type of treatment that helps the body's own defenses fight the disease.
This study is testing a blood test called AlloHeme that may help doctors predict whether your blood cancer will come back after a stem cell transplant. Joining this study could help you and your doctor monitor your recovery more closely.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.